Certest Biotec at ESGCT 2026

Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website

Certest Biotec brings 5 presentations to ESGCT 2026 in Hamburg. Its work centres on RNA medicines and the lipids that carry them. Projects cover ionizable and PEG-alternative lipid chemistry for organ-selective delivery, engineering untranslated regions to make messenger RNA translate better, and antisense oligonucleotides against drug-resistant bacteria.

OrganizationESGCT 2026 Attendance
Tools & reagents
Makes diagnostic tests and raw materials, including real-time PCR, sequencing and immunoassay kits, and has a pharma unit working on mRNA, lipid nanoparticles and antisense.
Poster
Wed Oct 28
1:30pm–3:30pm
END-RAM: Development of antisense oligonucleotide therapies against antimicrobial-resistant bacteria
Infectious diseases / Vaccines
RNA and oligonucleotide therapies
Poster
Wed Oct 28
1:30pm–3:30pm
Enhancement of mRNA translation efficiency through untranslated regions engineering
Other
RNA and oligonucleotide therapies
Poster
Thu Oct 29
2:00pm–4:00pm
Advancing lipid nanoparticle delivery through ligand-mediated active targeting
Non viral delivery
Poster
Thu Oct 29
2:00pm–4:00pm
PEG-alternative lipid technology for targeted RNA delivery
Non viral delivery
Poster
Thu Oct 29
2:00pm–4:00pm
Proprietary ionizable lipid families for clinically translatable, organ-selective and highly biodegradable nucleic acid delivery
Non viral delivery

Explore the full ESGCT 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Hamburg. Leave your work email and we’ll be in touch.

Privacy

Download the full ESGCT 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Certest Biotec

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction